Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
3-21-2013

Protective Effect of Surfactant Protein D in Pulmonary Vaccinia
Virus Infection: Implication of A27 Viral Protein
Julien Perino
Institut de Recherche Biomédicale des Armées- Antenne du Centre de Recherches du Service de Santé
des Armées

Nicole M. Thielens
Université Joseph Fourier

Erika Crouch
Washington University School of Medicine

Danièle Spehner
Université Louis Pasteur

Jean-Marc Crance
Institut de Recherche Biomédicale des Armées- Antenne du Centre de Recherches du Service de Santé
des Armées

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Perino, Julien; Thielens, Nicole M.; Crouch, Erika; Spehner, Danièle; Crance, Jean-Marc; and Favier, AnneLaure, ,"Protective Effect of Surfactant Protein D in Pulmonary Vaccinia Virus Infection: Implication of A27
Viral Protein." Viruses. 5,3. 928-953. (2013).
https://digitalcommons.wustl.edu/open_access_pubs/1407

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Julien Perino, Nicole M. Thielens, Erika Crouch, Danièle Spehner, Jean-Marc Crance, and Anne-Laure
Favier

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/1407

Viruses 2013, 5, 928-953; doi:10.3390/v5030928
OPEN ACCESS

viruses
ISSN 1999-4915
www.mdpi.com/journal/viruses
Article

Protective Effect of Surfactant Protein D in Pulmonary Vaccinia
Virus Infection: Implication of A27 Viral Protein
Julien Perino 1, Nicole M. Thielens 2, Erika Crouch 3, Danièle Spehner 4, Jean-Marc Crance 1
and Anne-Laure Favier 1,*
1

2

3

4

Laboratoire de Virologie, Institut de Recherche Biomédicale des Armées- Antenne du Centre de
Recherches du Service de Santé des Armées, 38702 La Tronche cedex, France;
E-Mails: julien0012000@yahoo.fr (J.P.) ; jeanmarccrance@orange.fr (J-M.C.);
favier03al@yahoo.fr (A-L.F.)
Institut de Biologie Structurale, CNRS, CEA, Université Joseph Fourier, Grenoble, France;
E-Mail: nicole.thielens@ibs.fr (N-M.T.)
Dept of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO,
USA; E-Mail: crouch@wustl.edu (E.C.)
IGBMC; CNRS, UMR 7104; Inserm U 596; Illkirch, F-67400 France; Université Louis Pasteur,
Strasbourg, F-67000 France ; E-Mail: spehner@igbmc.fr (D.S.)

* Author to whom correspondence should be addressed; E-Mail: favier03al@yahoo.fr (A-L.F.);
Tel.: +33-4-76-63-97-72; Fax: +33-4-76-63-69-06.
Received: 11 February 2013; in revised form: 11 March 2013 / Accepted: 12 March 2013 /
Published: 21 March 2013

Abstract: Vaccinia virus (VACV) was used as a surrogate of variola virus (VARV) (genus
Orthopoxvirus), the causative agent of smallpox, to study Orthopoxvirus infection. VARV
is principally transmitted between humans by aerosol droplets. Once inhaled, VARV first
infects the respiratory tract where it could encounter surfactant components, such as
soluble pattern recognition receptors. Surfactant protein D (SP-D), constitutively present in
the lining fluids of the respiratory tract, plays important roles in innate host defense against
virus infection. We investigated the role of SP-D in VACV infection and studied the A27
viral protein involvement in the interaction with SP-D. Interaction between SP-D and
VACV caused viral inhibition in a lung cell model. Interaction of SP-D with VACV was
mediated by the A27 viral protein. Binding required Ca2+ and interactions were blocked in
the presence of excess of SP-D saccharide ligands. A27, which lacks glycosylation,
directly interacted with SP-D. The interaction between SP-D and the viral particle was also
observed using electron microscopy. Infection of mice lacking SP-D (SP-D-/-) resulted in

Viruses 2013, 5

929

increased mortality compared to SP-D+/+ mice. Altogether, our data show that SP-D
participates in host defense against the vaccinia virus infection and that the interaction
occurs with the viral surface protein A27.
Keywords: orthopoxvirus; surfactant protein D; vaccinia virus; A27 protein; pulmonary
infection; innate immunity; surfactant protein A; KO mice; Ca2+; sugars

1. Introduction
Vaccinia virus (VACV) is the prototype for the Poxviridae family and the Orthopoxvirus genus
which includes variola virus (VARV), the etiological agent of smallpox. Since the eradication of
smallpox in 1980, vaccination was discontinued [1], resulting in a large proportion of the world
population susceptible to infection and heightened concerns about the threat of VARV as a bioweapon
[2]. VARV could easily be aerosolized and used for bioterrorism with significant morbidity and
mortality. VARV is principally transmitted between humans by aerosol droplets. Once inhaled, VARV
first infects the upper- or lower-respiratory-tract mucosa and can lead to severe systemic disease,
inducing death [3-5]. However, 70% of exposed individuals do not die of VARV infection,
emphasizing the importance of the immune response and possibly the innate immune defenses against
this pathogen.
The alveolar spaces and airways of the lung are lined by surfactant, which contains protein and lipid
components [6-7]. One lung protein of particular interest is surfactant protein D (SP-D), an important
innate immune effector with known roles in antiviral host defense to airway pathogens [8]. SP-D is a
member of the collectin subfamily of C-type lectins assembled from subunits comprising a triple
helical collagen domain and a C-terminal globular carbohydrate recognition domain (CRD) (Scheme
1A). This trimeric subunit can multimerize into assemblies of four or more trimers. In humans, the
collectin proteins also include surfactant protein A (SP-A) (Scheme 1B) and serum mannan-bindinglectin (MBL) [8-9], and show protein domain homologies to other complement recognition proteins
(L-, H- and M-ficolins). As a soluble collectin secreted into the airspaces, SP-D is mostly produced by
two types of pulmonary epithelial cells, alveolar type II cells and Clara cells and participates actively
in host defense when assembled as multimers. SP-D immune activity [10-11] results from its pattern
recognition activity towards multiple ligands present on bacteria, fungi, or viruses [12-15].
Binding requires the SP-D CRD and Ca2+, and SP-D can bind to a variety of carbohydrates in
addition to the N-linked glycans of glycoproteins [13, 16-17]. High affinity binding to saccharide
ligands requires trimerization of the CRD, which is mediated by the contiguous neck domain [18].
Binding to certain ligands can be inhibited by saccharide ligands, even though the interactions do not
appear to be mediated by the carbohydrate binding activity of SP-D [19-20]. In addition, SP-D binds
also to fatty acids in a Ca2+-dependent manner, and binding is inhibited by glucose. Although not
explained, this could reflect overlapping binding sites for carbohydrate and non-carbohydrate ligands
[21].
This specific activity ultimately leads to opsonization, agglutination and clearance of pathogens via
interaction with immune cells [22]. Protective roles of SP-D against various viral pathogens have been
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extensively studied, as for Influenza A virus (IAV) and respiratory syncytial virus (RSV) [23-30]. At
present, there is no evidence for the involvement of the lung collectins in innate host defense against
VACV.
Lung collectins are soluble pattern recognition receptors, previously demonstrated to interact with
fusion proteins from different lung viral pathogens. RSV G and F glycoproteins are involved in
binding of SP-D to RSV [26]. Similarly in the case of IAV, SP-D binds to the hemagglutinin (HA) [29,
31-32] by interacting with the carbohydrate residues on some IAV and eventually leading to pathogen
inactivation and clearance [33]. Inhibition by SP-D correlates with the presence of several glycan
attachment sites on HA. Pandemic and avian strains appear to lack susceptibility to SP-D, which
contributes to their virulence. IAV expressing the HA of pandemic viruses were associated with
significant pathology of the lower respiratory tract and showed a low binding activity for SP-D while
virus expressing HA of a seasonal strain induced only mild disease and exhibited strong in vitro
binding to SP-D [29, 34]. These studies established that the innate immune activity of SP-D is
principally mediated through interaction with viral membrane glycoproteins. Vaccinia virus A27
membrane protein (also named 14-kDa fusion protein), locates on the surface of the intracellular
mature virus (IMV) [35], plays an important role in virus-to-cell and cell-to-cell fusions [36-38]. This
highly antigenic protein, involved in virulence of VACV, is conserved among Orthopoxvirus genus,
and elicits neutralization antibodies [39]. A27 is involved in virus attachment to cell by binding
glycosaminoglycans [40-41] or sulfatide [42]. Interaction with GAGs was mediated by the negative
charge of the sulfate [40] that bound a stretch of positive amino acids of A27 (Lys/Arg-rich domain,
residues 21-31) [41, 43]. A27 was shown to have functional properties similar to those of HA of IAV,
except that the transmembrane domain is replaced by a domain involved in binding to A17 protein for
membrane anchoring [44-45]. The two proteins, localized on the virus surface, form trimers in the
virus particle [35] and are involved in virus penetration. The NH2-terminal region of A27 protein is
implicated in virus entry by direct fusion of the virus membrane with the cell plasma membrane [38,
41] or by receptor-mediated endocytosis followed by a low pH-induced fusion of viral and endosomal
membranes [46]. Accordingly, we hypothesized that SP-D might interact with A27 and participate in
the pulmonary defenses against VACV.
In addition to neutralizing virus in vitro, SP-D can enhance clearance in vivo. SP-D interacts with
influenza virus [47] resulting in the increase of the virus clearance from the lung of infected animals
[48-49]. Mice lacking SP-D (SP-D-/-) and wild type mice (SP-D+/+) were used as a model of infection
to clarify the relevance of these various in vitro studies to the physiological situation.
In the current paper, we studied the effect of collectins and particularly SP-D on VACV infection in
vitro and specifically the effect of SP-D in vivo. We demonstrated that SP-D was able to reduce VACV
infection and showed that the A27 virus protein was a potential partner of SP-D interaction. This study
represents a first approach to the involvement of SP-D in Orthopoxvirus infection and we suggest that
SP-D may be associated with innate defense against VACV.
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Scheme 1. Structure of SP-D and E321K SP-D NCRD mutant. (A) SP-D monomer
(illustrating CRD, neck, collagen-like and N-terminus domains) and SP-D trimer formed
by three monomers. (B) SP-D dodecamer formed by four trimers linked at the N-terminus
by disulfide bonds. (C) Illustration of Neck+CRD (NCRD) with a genetically engineered S
protein binding tag and His binding tag. CRD cartoons (green) representing the
carbohydrate binding groove flanked by amino acid residues 325–328 and 343–349,
associated Ca2+ ion (residue 321). Scheme adapted from [50].

2. Results and Discussion
2.1. Vaccinia virus interaction with surfactant protein D
The interaction of VACV with surfactant proteins (SP) was studied using a virus-protein overlay
assay (Figure 1). Solutions of purified VACV of three strains, Western-reserve, Lister and IHD-J were
dotted in replicates onto nitrocellulose membranes and incubated with surfactant protein solutions.
After extensive membrane washing, proteins bound to the membranes were detected using a specific
anti-surfactant protein antibody (anti-SP-A and anti-SP-D) and enhanced chemiluminescence. Weak
nonspecific binding was observed with the control membrane. Nonspecific signal was comparable to
the signals observed with human alveolar proteinosis surfactant protein A (AP-SP-A) and human
recombinant surfactant protein A (RhSP-A). RhSP-D was the only protein giving a strong interaction
with VACV from different strains.
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Figure 1. Binding of surfactant proteins to Vaccinia virus (VACV). Three VACV strains,
VACV-WR, VACV-Lister and VACV-IHD-J, were dotted onto membranes and incubated
with 2 µg of various surfactant proteins. After extensive washes, bound SPs were detected
with specific anti-surfactant protein antibodies and revealed by enhanced
chemiluminescence (ECL). Mock membrane was incubated with specific anti-SP
antibodies. RhSP-D and RhSP-A, dotted onto SP control membrane, were revealed with
specific anti-SP antibodies. AP-SP-A, human SP-A from alveolar proteinosis; RhSP-A,
recombinant human SP-A; RhSP-D, recombinant human SP-D.
Mock

RhSP-D

RhSP-A

AP-SP-A SP control

VACV-WR - RhSP-D
VACV-List - RhSP-A
VACV-IHDJ -

2.2. SP-D inhibits VACV infectivity
A plaque assay was used in order to determine consequences of SP-D interaction on virus infection.
VACV-WR was pre-incubated with SP-A and SP-D proteins (Figure 2A). Under these conditions, the
protein suspensions did not induce any cytotoxicity (data not shown). Bovine serum albumin did not
modify the virus infection (p>0.05, two-tailed unpaired Student’s t-test). Pre-incubation of VACV-WR
with AP-SP-A or with RhSP-A had no neutralizing activity as observed in the plaque assay (p>0.05,
two-tailed unpaired Student’s t-test). By contrast, incubation of virus with SP-D resulted in strong viral
neutralizing activity (53 %) when compared with non pre-incubated virus (p<0.0001, two-tailed
unpaired Student’s t-test). To characterize SP-D-virus interaction, increasing concentrations of RhSPD (0.15, 0.30 and 0.60 µg/mL) were pre-incubated with the same amount of VACV (Figure 2B). No
inhibition of infection was observed with bovine serum albumin while RhSP-D induced a statistically
significant dose-dependent inhibition of VACV-WR from 0.15 to 0.60 µg/mL (p=0.0033, p=0.0001
and p<0.0001, respectively; two-tailed unpaired Student’s t-test). Therefore, the activity of RhSP-D on
VACV was confirmed and characterized as a dose-dependent inhibition.
2.3. Multimeric SP-D but not NCRD domains inhibits VACV infectivity
The inhibiting activity from full length SP-D protein was compared with trimeric NCRD domains
(neck + carbohydrate recognition domain) derived from human and rat sequences (see protein structure
in Scheme 1A). NCRDs were used to further characterize the requirement for multimerization of the
native protein SP-D to induce viral inhibition. The human E321K mutant (mutNCRD) was previously
described for its lack of HA inhibitory activity [51], resulting from the mutation of a residue involved
in the coordination of calcium at the lectin site (Scheme 1C). No viral inhibition was obtained with
BSA nor with any of the tested NCRD (Figure 2C) (p>0.05, two-tailed unpaired Student’s t-test) in
contrast with full length SP-D protein (53% inhibition) (p<0.0001, two-tailed unpaired Student’s ttest). Additional experiments performed at 10 µg/mL of NCRD did not induce viral inhibition (data not

Viruses 2013, 5

933

shown). In these conditions, results suggest that the NCRD domain is not sufficient and that the
multimeric state of full length protein is mandatory for efficient viral inhibition.

Figure 2. Virus infection inhibition assay. VACV-WR was incubated with proteins for 1 h.
A549 cells were infected at a MOI of 0.0001 and virus replication was measured by a PFU
assay. VACV-WR pre-treated groups were compared to the VACV-WR group. An asterisk
indicates a statistically significant difference (p<0.05, two-tailed unpaired t-test).
Incubation (A) with 0.6 µg/mL of BSA, AP-SP-A, RhSP-A or RhSP-D; (B) with
increasing RhSP-D doses. Symbols: ■, VACV-WR+RhSP-D; □, VACV-WR+BSA. (C)
VACV-WR was incubated with 0.6 µg/mL of RhSP-D and 2 µg/mL of NCRD domain of
SP-D from human (hNCRD), rat (rNCRD), or human E31K mutant (mutNCRD) for 1 h.
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2.4. Comparison of infection inhibiting activity of SP-D with other human defense lectins
SP-D is belonging to collectins which are oligomeric proteins consisting of collagen stalks and
globular carbohydrate recognition domains. The other collectin MBL and the related proteins L-, Hand M-ficolins were tested for viral inhibition in comparison to SP-D (Supplementary data 1). Equal
quantities of proteins were tested in this experiment. SP-D was the only collectin leading to VACVWR infection inhibition (about 50% of inhibition) (p<0.0001, two-tailed unpaired Student’s t-test).
2.5. Recombinant A27 viral protein binds to SP-D
The binding of A27 protein to SP-D was investigated in vitro using an ELISA assay. A27 viral
protein is a membrane protein localized on the surface of the IMV, the most abundant virus form
produced in infected cells known to be responsible for the initiation of infection. An E. coli expression
system was used because A27 protein produced in this system was shown to exhibit structural and
functional properties similar to those found in the virus particle and in virus-infected-cells [52]. To
determine the involvement of the A27 viral protein in SP-D interaction, A27 was expressed in a
soluble form in E. coli, and purified by nickel affinity chromatography using the hexahistidine tag at
the N-terminus of the recombinant protein. As determined by SDS-PAGE analysis, in denaturing and
reducing conditions A27 migrated as one band (14 kDa, monomer) detected by Coomassie blue
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staining and as two bands (an additional minor band at 20 kDa) that was detected by western-blotting
(Figure 3A, lane 1). In non-reducing conditions, A27 spontaneously assembled into trimers (Figure
3A, lane 2). Despite the same amount of protein applied in each lane, a difference in A27 band
intensities (lanes 1 and 2) was observed which may result from the weaker capacity of the monoclonal
antibody to react with the monomeric state of A27. N-glycosidase F digestion experiments confirmed
the expected absence of sugars (data not shown).
The interaction of SP-D with A27 was examined onto microtiter wells (Figure 3B). Coated proteins
were incubated with RhSP-D. Bound RhSP-D was detected with a specific antibody against SP-D. A
mix of HA of IAV was used as a positive control of interaction. RhSP-D interacted with A27 in
presence of Ca 2+ whereas the binding was abolished for both HA and A27 proteins, in the absence of
Ca 2+. The experiment indicated that the binding of SP-D to A27 is Ca2+-dependent.
Contribution of NCRD domains in the interaction between SP-D and A27 was examined in
microtiter wells (Figure 3C). Coated proteins were incubated with hNCRD or mutNCRD in presence
of Ca 2+. Bound NCRDs were detected with a specific antibody against SP-D. A mix of HA of IAV
was used as a positive control of interaction. A weak interaction was obtained for hNCRD with both
A27 and HA whereas no binding of mutNCRD to HA was observed. The experiment suggested that
NCRD of SP-D could contribute to the interaction with A27. The weak interaction of hNCRD with
A27 was maintained with the mutNCRD, suggesting the region of the CRD near to, but distinct from,
the lectin site contributed to the interaction.
We next studied whether monoclonal antibodies (mAbs) directed against the A27 protein of VACV
could prevent the interaction between A27 and hNCRD, using a protein-protein overlay assay (Figure
3D). A27 solutions were dotted in replicates onto nitrocellulose membranes and incubated with
hNCRD. After extensive membrane washing, bound hNCRD was detected using S protein-HRP
antibody (anti-His antibody was avoided as both hNCRD and A27 were His-tagged proteins) and
enhanced chemiluminescence. No binding was observed with the control spots (mAbs alone). A weak
specific signal was observed with A27 and hNCRD compared to HA of IAV and hNCRD. No
inhibition was observed with control mouse IgG while mAb against A27 (5B4) partially inhibited the
A27-hNCRD interaction.
To clarify the finding obtained with NCRD, a higher oligomeric structure of NCRD was tested
using the capacity of the multivalent S protein-HRP to generate aggregates of NCRD containing the S
protein binding site [53] [28]. In fact, NCRD contains an S protein binding site, which can be detected
by the S protein conjugated with HRP and subsequently used to detect the binding to various ligands.
Preincubation of hNCRD with the S protein-HRP complex resulted in considerably increased binding
to A27 compared to the situation where hNCRD is added to the viral protein followed by addition of
S-protein-HRP (Figure 3E). A similar result was obtained with HA (data not shown), thus indicating
that multivalency of NCRD is required to potentiate the interaction with A27.
Figure 3. A27 viral protein interacts with SP-D. (A) Characterization of the recombinant
A27 protein. The purified recombinant A27 protein (0.5 µg/lane and 2 µg/lane for
Western-blot (left panel) and 12% SDS-PAGE analysis (right panel), respectively) was
heated at 100°C for 5 min in denaturating, reducing sample buffer (lane 1) or incubated for
5 min at room temperature in non-reducing sample buffer (lane 2). RhSP-D (2.5 µg/ml) (B)
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or hNCRD and mutNCRD (5 µg/ml) (C) were incubated for 1 hour at 37°C with coated
proteins on 96-multiwell plate. Bound RhSP-D was revealed with a rabbit anti-SP-D
specific antibody and with a goat anti-rabbit-HRP antibody. TMB substrate was added and
OD was measured at 450 nm. An asterisk indicates a statistically significant difference
(n=3; p<0.05, two-tailed unpaired t-test). (D) Interaction between A27 and hNCRD was
partially inhibited with mAbs against A27. A27 was preincubated with mAbs at 10 µg/mL.
1 µg of A27 protein was dotted onto membrane and incubated with hNCRD (5 µg/mL). 0.5
µg of hNCRD was dotted onto the membrane as positive detection control. After extensive
washes, bound hNCRD was detected with specific S protein-HRP antibody and revealed
by enhanced chemiluminescence (ECL). (E) Both A27 protein and BSA were coated on
96-multiwell plate. A range (2, 5, 7, 15 and 30 µg/mL) of hNCRD alone or hNCRD
preincubated with S protein-HRP (1:20, concentration) was incubated for 1 hour at 37°C.
Preincubation of hNCRD with S protein-HRP noticeably increased binding of hNCRD to
A27. BSA, bovine serum albumin; HA, hemagglutinin of IAV; A27, A27 viral protein of
VACV (14-kDa fusion protein). Incubation was performed in the absence (-) or presence
(+) of 5 mM Ca 2+.
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2.6. Visualization of the interaction of SP-D to VACV particle by electron microscopy (EM)
To further study the interaction between SP-D and VACV viruses, electron microscopy was
performed on inactivated VACV-WR incubated with RhSP-D (Figure 4). After negative staining, the
VACV particles were observed by EM (Figure 4A). The electron micrographs showed the polymeric
forms of RhSP-D as previously described for both bronchoalveolar lavage purified SP-D and RhSP-D
as “astral bodies” [54-55]. Preparation contained only some dodecamers (cruciform structures) and a
majority of higher order multimers of RhSP-D (Figure 4B). The globular heads of SP-D, containing
the CRD, can be seen especially on the periphery of the radially symmetric multimers. In presence of
the virus particle, no interaction was observed with SP-A (data not shown) whereas SP-D interacted
with the surface of the virus particle, which binds at one part of the virus particle (Figure 4C).
Figure 4. Electron Microscopy of virus particle interacting with SP-D. The interaction
between inactivated VACV-WR and RhSP-D was illustrated. Panel A represents the
inactivated virus. Panel B represents the control of RhSP-D (arrows: dodecamer, cruciform
structure; and arrow heads: higher order multimers). Panel C displays the interaction and
the site of attachment (arrows) between VACV-WR and RhSP-D; arrow heads represent
isolated protein. The bar corresponds to 100 nm.
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100nm
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100nm
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100nm
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2.7. Analysis of SP-D binding to VACV by surface plasmon resonance (SPR) spectroscopy
2.7.1. SP-D binding to viral particle
SPR spectroscopy was used to further characterize the interaction of SP-D with VACV. First, the
well characterized interaction between HA of IAV and SP-D was verified by SPR, allowing for
confirmation of previous studies using other techniques [23, 31, 47]. Soluble HA bound in a dosedependent manner to immobilized SP-D in the presence of calcium ions (Figure 5A). Kinetic analysis
of these binding data yielded association and dissociation rate constants of 0.7 x 105 M-1 s-1 and 1.2 x
10-4 s-1 respectively, using global fitting to a 1:1 Langmuir interaction model. The deduced apparent
equilibrium dissociation constant (KD) was 0.53 nM, indicative of high affinity. However, due to the
oligomeric nature of both SP-D and HA, it cannot be excluded that some rebinding might occur during
the dissociation phase, thus enhancing the apparent stability of the complex. Inhibition of the
interaction between HA and SP-D was obtained using maltose and EDTA (Figure 5B).
Injection of various concentrations of iVACV over immobilized SP-D (Figure 5C), yielded dosedependent responses ranging from 50 to 200 resonance units using equivalent titers of iVACV ranging
from 2.108 to 2.109 virus /mL (corresponding to 1/100 and 1/10 dilutions, respectively). The affinity of
the interaction could not be quantified since determination of the dissociation constant requires precise
knowledge of the molar concentration of the soluble interactant, which does not apply to a viral
particle with many surface-exposed potential ligands. Using a fixed viral dose (D=1.109 equivalent
titer of inactivated virus /mL), different potential inhibitors were tested (Figure 5D). Inhibitors of
specific CRD attachment, maltose, mannose and mannan induced 32%, 36% and 53% of inhibition at
this specific dose, respectively. The calcium chelator induced a strong inhibition of 78% (Figure 5D).
These results showed the calcium-dependence of the interaction between VACV and SP-D and the
inhibitory effect of sugar ligands of SP-D, thus strongly suggesting the involvement of the
carbohydrate-binding domain of the collectin.
2.7.2. Characterization of the interaction between SP-D and recombinant A27
HA of IAV was demonstrated to strongly interact with SP-D (see Figure 5A), moreover it was
shown to present common domains and function with A27 vaccinia virus protein [35]. To determine
A27 protein involvement in SP-D interaction with VACV, trimeric recombinant A27 was immobilized
on a sensor chip and binding of SP-D to A27L analyzed using SPR spectroscopy (see Figure 5E). SPD bound to A27L in a dose-dependent manner and the dissociation was very slow, reflecting the great
stability of the complex (Figure 5E). Determination of the kinetic parameters yielded ka and kd values
of 5.8 x 105 M-1 s-1 and 8.9 x 10-5 s-1, with a resulting apparent KD value of 0.15 nM, indicative of
strong affinity. Again, these values are only apparent due to the multivalent nature of the interaction,
but they are in the same range as those obtained for the interaction of HA with SP-D under the same
conditions. Inhibition of interaction was also observed in the presence of maltose and EDTA (Figure
5F).
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Figure 5. SPR analysis of the interaction of VACV with immobilized SP-D. VACV-WR
particle binding to SP-D: (A) SPR analysis of the interaction of HA with immobilized SPD. HA of IAV was injected at concentrations of 0.5, 1, 2, 3, 5 and 8 nM over immobilized
SP-D. (B) HA (3 nM) was injected over immobilized SP-D in the presence of selected
competitors of SP-D-ligand interaction (5 mM maltose or 3.4 mM EDTA). (C) iVACV
was injected at various concentrations ranging from equivalent titer 2.10 8 to 2.109 virus/mL
(corresponding to 1/100 to 1/10 dilutions, respectively) over immobilized SP-D. (D)
iVACV (1/20 dilution) was injected over immobilized SP-D in the presence of competitors
of SP-D interaction with carbohydrates (10 mM maltose, 10 mM mannose, 100 µg/mL
mannan or 3.4 mM EDTA). All results are representative of two independent experiments.
Sensorgrams were distorted at the beginning and end of injections due to solvent effect.
Binding of SP-D to viral A27 protein: (E) Purified SP-D was injected at concentrations of
1.7, 3.4, 6.8, 9.1 and 13.7 nM over immobilized A27. (F) SP-D (6.8 nM) was injected over
immobilized A27 in the presence of 5 mM maltose or 3.4 mM EDTA. Results are
representative of two independent experiments.

(A) Immobilized SP-D

270
180
90
0
0

80

160
240
Time (s)

(C) Immobilized SP-D

320

5 nM
3 nM
2 nM
1 nM
0.5nM
400

3 nM

200
150
100

5 mM maltose

50
0

3.4 mM EDTA
0

80

160
240
Time (s)

1/10

180

150

1/20

120

1/40

60

1/100

0
0

200

400

600 800
Time (s)

(E) Immobilized A27

13.7 nM
9.1 nM
6.8 nM
3.4 nM

40

3.4 mM EDTA
0

1.7 nM

200

400

600 800
Time (s)

1000 1200

(F) Immobilized A27

SP-D

80

VACV-WR

10 mM Maltose
10 mM Mannose
100 µg/mL Mannan

0

1000 1200

120

400

1/20

100
50

320

(D) Immobilized SP-D

VACV-WR

200

SP-D

75

Response (RU)

Response (RU)

8 nM

360

Response (RU)

HA of IAV

250

450

Response (RU)

(B) Immobilized SP-D

HA of IAV

540

6.8 nM

50
25

5 mM Maltose
3.4 mM EDTA

0

0
0

60

120
180
Time (s)

240

300

0

60

120
180
Time (s)

240

300

Viruses 2013, 5

939

2.7.3. Characterization of the interaction of A27 with other proteins of the defense collagen family
The capacity of other proteins of the defense collagens family to interact with A27L was tested by
monitoring binding of the proteins to immobilized A27 using SPR spectroscopy (Supplementary data
1B). As shown in the upper panel, all proteins tested bound to A27, although clearly to different
extents: the binding level for MBL was in the same range as that of SP-D, whereas the three human
ficolins, especially M- and H-ficolins, exhibited poor A27 binding capacity. We decided next to
determine if the NCRD domain from SP-D was sufficient to mediate interaction with A27
(Supplementary data 1B, lower panel). Human NCRD (hNCRD) and E321K, a mutant NCRD
(mutNCRD) with impaired binding capacity to a variety of microorganisms recognized by SP-D [50]
showed a weak interaction with A27. When using a 90 nM concentration of hNCRD, a weak
interaction was detected. However, similar results were obtained at a concentration of 900 nM thus
casting doubts about the specificity of the observed interaction (data not shown). Both SP-A (RhSP-A
and AP-SP-A) showed no interaction with A27 (lower panel). Among the tested lectins, SP-D showed
the strongest interaction with A27. Because trimeric NCRD was inactive, the data suggest important
cooperative interactions among CRDs.
2.8. Protective role of SP-D in VACV infection in mice model
To address the role of SP-D in VACV susceptibility in vivo, SP-D+/+ and SP-D-/- (deficient in SP-D)
were infected with VACV-WR by intranasally instillation. The VACV-WR strain, shown to bind SP-D
in vitro, was chosen because of its ability to induce death in mice [56]. LD50 calculated on SP-D+/+
mice was estimated at 5 x 105 PFU (data not shown). The experiment was performed three times with
comparable and significant results, one representative experiment being shown (Figure 6). At 1 LD50
inoculating dose, VACV-WR was responsible for about 50% death of SP-D+/+ mice whereas all
uninfected animals survived. Difference in survival was observed between VACV-infected SP-D+/+
and VACV-infected SP-D-/- mice groups. In the absence of SP-D, the pathogenesis of VACV was
increased, only 23% infected SP-D-/- mice survived compared to 50% in the infected SP-D+/+ mice
group (p=0.0069; Log Rank test).
The importance of the lung as a primary target during respiratory transmission of variola virus
highlighted the importance to study influence of surfactant during infection [42]. It is likely that lung
surfactant defense proteins play a role in containing the beginning of the infection [23]. Surfactant
innate defense system is mainly composed of collectins and phagocytes. Collectins or C-type lectins
are composed of polypeptides including mannan-binding lectin, bovine conglutinin and two surfactant
proteins: SP-A and SP-D. This family shares structural features such as a collagenous N-terminal
domain, a neck and a globular C-terminal domain which is implicated in carbohydrate recognition
leading to pathogens opsonization and clearance [57].
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Figure 6. SP-D protected mice against VACV-WR. Five week old Black Swiss mice SPD+/+ and SP-D-/- were infected intranasally with 1 LD50 of VACV-WR. Survival was
monitored for 17 days. SP-D-/- group was compared to SP-D+/+ group and to a mockinfected group (Log Rank test).
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This study provides the first evidence for an inhibitory effect of SP-D on poxvirus infectivity in
vitro and its exclusive activity compared to other collectins. Among pulmonary collectins, SP-D was
the only protein leading to a strong interaction with VACV in our study. Three strains of VACV were
tested (Western Reserve, Lister and IHD-J) and no difference was observed. SP-A (recombinant and
alveolar proteinosis purified forms) was unable to interact with any viral strain contrary to SP-D,
which strongly interacted with all strains in a similar manner. These results demonstrated a specificity
of binding between SP-D and VACV contrary to Influenza A Virus (IAV) that interacts with both SPA and SP-D [47, 58].
Using a pulmonary cell line, this interaction was directly linked to the ability of SP-D to inhibit
virus infection when using a pre-incubation plaque assay. Implication of Neck + Carbohydrate
Recognition Domain (NCRD) was tested but no inhibition was obtained with any of the two
recombinant NCRD domains (human and rat). This result indicates that purified NCRD alone is not
sufficient but may require higher level of organization (multimerization) for being active or that full
length protein is needed for inhibition activity. A similar result was previously described for IAV, with
native SP-D being protective in vivo but not wild-type NCRD alone [53] [28]; however, certain mutant
NCRDs with greatly enhanced IAV binding activity did show antiviral activity in vivo [59-60].
Influenza A virus is one of the most extensively respiratory virus studied. Its interaction with SP-D
was widely studied and authors agreed that HA mediated-interaction is sugar inhibited and Cadependent, resulting from the involvement of CRD. While we could confirm these observations
between for HA of IAV by ELISA and SPR spectroscopy, we could not completely elucidate the
mechanism of interaction between A27 and SP-D. SPR spectroscopy experiments showed that SP-D
was able to interact with VACV in a dose-dependent manner and that the carbohydrate recognition
domain (CRD) should be implicated because of binding inhibition by sugars and EDTA. In the same
manner, a Ca2+-dependent interaction was first observed between SP-D and A27 coated on microtiter
plates. The lack of neutralization of virus infection in plaque assay by NCRD and the weak interaction
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observed between A27 and hNCRD suggested that the involvement of NCRD domain alone (trimeric
form) is not sufficient whereas the multimerization of NCRD (higher oligomeric form using S proteinHRP) resulted in a marked interaction. The involvement of multimerized NCRD domains could not be
confirmed by SPR due to difficulties of interpretation of the data (presence of glycerol in S proteinHRP).
Although it appears clear that efficient binding requires oligomerization of the CRDs, the
mechanism of SP-D interaction with A27 was not entirely clarified. On the one hand, the fact that the
binding is inhibited by calcium chelation and in the presence of maltose suggests an involvement of
the lectin activity of SP-D. On the other hand, the fact that the weak interaction with NCRD was
maintained with the E321K mutant devoid of lectin activity and that the A27 protein is not
glycosylated favors the hypothesis of a protein-protein interaction. The interaction of SP-D with A27
appears thus different from that of SP-D with HA, known to involve N-linked carbohydrates of the
viral protein [61]. It is rather reminiscent of previous data on the interaction of SP-D with the
extracellular domain of TLR-2 and -4, showing that N-linked oligosaccharides are not required and
suggesting an involvement of amino acid residues close to the ligand binding site of SP-D [19].
Alternatively, binding of the CRD to a ligand such as maltose may induce conformational changes and
impair subsequent interaction with A27. Anti-SP-D monoclonal antibodies would be helpful to further
identify the SP-D sequence that supports binding to A27 [19]. In the same manner, a mutant of the
multimeric SP-D protein with a non-functional NCRD (e.i E321K mutation) would be useful to
determine which domain is important for binding to A27.
Among surfactant proteins, SP-D was the only protein able to inhibit viral infection when using a
pulmonary cell line and the soluble defense collagens tested (SP-A, MBL and the three human ficolins
(H, L and M)) were unable to induce inhibition. However, SPR experiments showed that some of these
proteins interacted with A27 (MBL, L-ficolin and M-ficolin). This apparent discrepancy is reminiscent
of previous observations of MBL interaction with Ebola virus. Even if MBL could bind, interact and
block Ebola envelope glycoprotein-mediated virus binding to DC-SIGN, MBL was unable to directly
neutralize the virus without the presence of complement in neutralization assays [62]. In the same
manner, neutralization of influenza virus by MBL was complement-dependent [63]. Little information
is available concerning the interactions between ficolins and viruses. In contrast, neutralization of
viruses by SDP-D was observed in the absence of complement, conditions in which our experiments
were performed. It should be mentioned that, contrary to SP-D, interaction of MBL and ficolins with
viruses is expected to activate the lectin complement pathway, leading to opsonization of the virus by
C3b fragments for subsequent phagocytosis.
Inhibition of VACV in an epithelial airway cellular model led us to use a SP-D-deficient mice
model. The mortality of VACV-infected mice was increased in the absence of SP-D, suggesting the
involvement of SP-D to neutralize VACV infection. Future experiments could be performed by
measuring virus titers in lung, cells recruitment [48] [64], pro-inflammatory cytokine production [49]
[48] and histopathological changes to explain the difference of mortality between SP-D -/- and wildtype mice and to address the significance of SP-D in protection against VACV infection.
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3. Experimental Section
3.1. Cells and viruses
A549 cells (human lung carcinoma cell line, ATCC CCL-185) were grown in F12K medium
(Gibco). BHK-21 cells (hamster kidney cells, ATCC CCL 10) were grown in Glasgow minimum
essential medium (Gibco) supplemented with 10% tryptose phosphate (Sigma) and 50 mM HEPES
(Gibco). Vero cells (African green monkey kidney cells, ATCC CCL 81) were grown in M199
medium (Gibco). For cell culture, all media were supplemented with 10% inactivated fetal calf serum
(FCS), whereas medium for infection was supplemented with 5% FCS and 1% antibiotics (100 U/mL
of penicillin and 100 µg/mL of streptomycin, Gibco). Cells were cultured at 37°C in a 5% CO 2
atmosphere. Cytotoxicity was determined by trypan blue staining and cell counting. The vaccinia virus
Western Reserve strain (VACV-WR) was obtained from the ATCC (ATCC VR-119), the firstgeneration Lister smallpox vaccine (VACV-List, X55-33) was provided by the French health
authorities and the vaccinia virus IHD-J strain (VACV-IHDJ) was obtained from the ATCC (ATCC
VR-156). All virus strains were produced in BHK-21 cells, intracellular mature viruses were purified
using sucrose density gradient centrifugation as previously described [65]. Virus was stored in 10 mM
Tris-HCl (pH 8) at -80°C. Virus productions were titrated in Vero and A549 cells. Before infection,
cells were rinsed and infected with virus in culture medium supplemented with 0.5% FCS and 1%
antibiotics. Purified viruses were inactivated (iVACV) for some experiments using a previously
described protocol [66]. Briefly, 100 µL were mixed with 1 µL Psoralene solution (Sigma, 1mg/mL in
DMSO) and exposed during 1 hour to an UV light (365 nm) in a tissue culture plate 48 multi-wells
plate. Equivalent titer of iVACV was 2 x 1010 plaque forming units (PFU)/mL.
3.2. Reagents
Rabbit anti-surfactant antibodies raised against SP-A and SP-D proteins were purchased from
Millipore (AB3420 and AB3434, respectively). Rabbit anti-vaccinia whole virus antibody was
purchased from Fitzgerald-Interchim (20VR-69) and both peroxydase-conjugated goat anti-rabbit and
anti-mouse IgG antibodies were purchased from Jackson ImmunoResearch. Mouse monoclonal antiHis antibody was purchased from Qiagen (34 660). The mouse monoclonal anti-A27 antibody (5B4)
was obtained from C.P Czerny and the mouse monoclonal anti-VACV antibody (B608M) was
purchased from Abcam (Ab48569). Peptide:N-glycosidase F (PNGase F) was purchased from Sigma
(P7367). A mix of recombinant HA proteins of IAV were obtained from Vaxigrip®
(A/Brisbane/59/2007 (H1N1); A/Brisbane/10/2007 (H3N2); B/Florida/4/2006). Predicted molecular
size of HA (trimeric protein) was 180 kDa (extracellular domain). S protein-HRP conjugate was
purchased from EMD Chemicals, Inc (69047-3).
3.3. Recombinant surfactant proteins
Recombinant human SP-D dodecamers were expressed in CHO-K1 cells and purified as previously
described [55]. Recombinant trimeric neck + carbohydrate recognition domain fusion proteins
(NCRDs) from human (hNCRD and the E321K mutant (mutNCRD)) and rat (rNCRD) species were
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expressed in bacteria and purified as previously described [57] [50]. All preparations used for these
studies had low endotoxin (45.2 ng LPS/mg of RhSP-D protein; 20 ng LPS/mg of hNCRD; 0.56 ng
LPS/mg of rNCRD; 0.27 ng LPS/mg of mutNCRD). AP-SP-A was a kind gift from Dr J.R. Wright
(Duke University, Durham, USA). Recombinant RhSP-A was kindly provided by Dr F. McCormack
(University of Cincinnati, Cincinnati, USA). The molecular size of proteins was estimated as followed:
516 kDa for RhSP-D (composed of twelve identical polypeptides of 43 kDa) and 72 kDa for both
hNCRD and mutNCRD (composed of three identical CRD domain of 24 kDa).
3.4. Other recombinant proteins
Human recombinant wild-type M-ficolin was expressed in S2 insect cells and purified as described
previously [67]. L-ficolin was purified from serum as described previously [68]. Recombinant human
MBL and H-ficolin were produced in CHO cells and purified as described by Teillet et al. [69] and
Lacroix et al. [70], respectively.
3.5. A27 viral protein expression and purification
The gene coding for full length A27 protein (A27L) was amplified from Lister strain of VACV
(Pourquier
vaccine)
using
the
following
primers:
A27
sense
primer:
5’GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGACGGAACTCTTTT3’
and
A27
antisense primer: 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACTCATAT
GGACGCCG3’. A27L construct was finally cloned in pDEST TM17 (Invitrogen, Gateway technology)
using the following primers: attB1-A27LS :
5’GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGACGGAACTCTTTT 3’ et attB2A27LR : 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACTCATATGGACGCCG 3’ and
transformed in BL21 (DE3) pLysS. The recombinant A27 protein (rA27) contained an N-terminal Histag by analogy with previous studies showing that an N-terminal T7 tag peptide did not interfere with
the function of the corresponding A27 construct [36-38]. Colonies were used to inoculate 1 L of LB
containing appropriate antibiotics. Cells were grown in shakers at appropriate temperature (37°C) and
speed (200 rpm) until reaching 0.6 OD at 600 nm. Expression was induced with 1mM final
concentration of IPTG for 4.5 hours at 37°C. Pellets were harvested after centrifugation (10000g, 5
min, 4°C). They were resuspended in lysis buffer (Tris-HCl 1.5 M, pH 7.3), then sonicated and
supernatant was harvested. Recombinant N-terminal-His tagged protein was loaded on a His TrapTM
HP column (Amersham Biosciences) and eluted using buffer containing 20 mM sodium phosphate,
500 mM NaCl and 500 mM imidazole. Purified protein was dialyzed overnight against PBS and
quantified using Bradford assay. 240 µg of purified rA27 (Quick Start Bradford Protein Assay) was
obtained from 1 L of induced bacteria. The expected amino acid sequence of rA27 was
MSYYHHHHHHLESTSLYKKAGLMDGTLFPGDDDLAIPATEFFSTKAAKKPEAKREAIVKADE
DDNEETLKQRLTNLEKKITNVTTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQ
TGRRPYE, underlined residues corresponding to A27. The monomeric and trimeric forms of the A27
protein were detected by electrophoresis on a 12% SDS-polyacrylamide gel under reducing and nonreducing conditions, respectively, and protein profiles revealed by western-blot analysis and ECL
detection and autoradiography using a mouse monoclonal anti-His antibody.
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3.6. A27 SDS-PAGE and western-blot analyses
A27 recombinant protein was subjected to SDS-PAGE (12%) under reducing and non-reducing
conditions. Using western-blot method, A27 protein was revealed using an anti His antibody and a
HRP-labeled goat anti-mouse IgG antibody. The peroxidase reaction was assessed by using ECL. The
purified recombinant A27 protein (0.5 µg) was digested by 15 U peptide:N-glycosidase F (PNGase F)
for 10 hours at 26°C.
3.7. Surfactant protein interaction with VACV strains by overlay assay
Purified mature viruses of VACV-WR, VACV-List and VACV-IHDJ strains were dotted on
membranes. Duplicates of viral solutions (2 µg/spot, Bradford virus titration) were spotted onto
HybondC-extra nitrocellulose membranes (Amersham) and allowed to dry in the dark at room
temperature (RT) for one hour. Membranes were blocked for one hour at RT in TBS containing 0.5%
Tween 20, CaCl2 5 mM and 3% fatty acid-free BSA (Sigma). The membranes were then incubated
overnight at RT in the same buffer containing 1 µg/mL surfactant proteins. The membranes were
washed three times for 10 min and then incubated for 1 h at room temperature with the rabbit anti-SPA or anti-SP-D antibody (1/1000 containing 3% BSA). After four 20-min washes, the membranes were
incubated for 1 h with anti-rabbit horseradish peroxidase conjugate (1/10000 dilution). Finally, after
six 10-min washes, the interactions were detected by enhanced chemiluminescence (ECL).
3.8. hNCRD interaction with A27 by overlay assay
Purified A27 and HA (1 µg/spot) were dotted onto HybondC-extra nitrocellulose membranes
(Amersham). Membranes were blocked for 1 hour at RT in TBS containing 0.05% Tween 20, CaCl2
10 mM and 5% milk. A27 was preincubated with mAbs (clone 5B4, Abcam (B608M) and mouse Ig)
for 30 minutes at 37°C at 10 µg/mL. The membrane was then incubated overnight at 4°C in the same
buffer containing 5 µg/mL hNCRD. The membranes were washed three times for 20 min and then
incubated for 1 h at room temperature with the S protein-HRP antibody (1/10,000). After three 20-min
washes, interaction was detected by enhanced chemiluminescence (ECL).
3.9. Lectins-virus infection inhibition assay
A549 cells were seeded to obtain confluent plates after 48 hours of culture in 12 multi-wells plates.
VACV-WR was incubated with 0.6 µg of SP-D, MBL, ficolins or 2 µg of human, rat and mutated
E321K human NCRD for 1 hour at 37°C. During this time, cells were rinsed with fresh F12K medium
0.5% FCS and 1% antibiotics. Then, virus-protein mixes were incubated with cell monolayer
(multiplicity of infection, MOI 0.0001) at 37°C in 5% CO 2 atmosphere during one hour. Cells were
rinsed with 0.5% FCS medium and covered with 1.5 mL fresh F12K medium 5% FCS, and cultured
for an additional 48 hours. Cells were fixed by adding 0.75 mL of fixing and staining solution (0.2%
crystal violet, 4.5% formaldehyde and 7.5% ethanol in PBS) per well for 2 hours. Wells were rinsed
twice with water and PFU were counted. Experiment was performed three times. Additional
experiment was performed at 10 µg of human NCRD.
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3.10. Binding of SP-D to A27 recombinant VACV protein
A27, HA mix of IAV (Vaxigrip®), SP-D, hNCRD and mutNCRD (100 ng/well in 100 mM Na2CO3
pH 9.6) were coated onto microtiter wells overnight at 4°C, and nonspecific binding was blocked with
PBS buffer without Ca and Mg (BioWhittaker) containing 5% (w/v) fatty acid-free BSA, 0.05% tween
and 5 mM CaCl2 (buffer A) for 1 hour at 37°C. SP-D (2.5 µg/mL) or NCRD (5 µg/mL) in buffer A
was added and incubated at 37°C for 2 hours. After the incubation, the wells were washed with buffer
A and further incubated with rabbit anti-SP-D polyclonal antibodies followed by incubation with
peroxidase-conjugated goat anti-rabbit IgG antibody. The peroxidase reaction was finally conducted
by using TMB substrate (Sigma), and the absorbance at 450 nm was measured. Some incubations were
also performed in the absence of Ca2+.
3.11. ELISA assay for measurement of binding of NCRDs to A27 recombinant VACV protein
Binding of trimeric NCRD fusion proteins to A27 protein of VACV was measured as previously
described using the S protein-HRP conjugate (Novagen) [53]. In brief, ELISA plates were coated with
A27 protein (10 µg/mL, 50 µL per well) followed by washing and addition of a range (2, 5, 7, 15 and
30 µg/mL) of NCRD alone or NCRD that had been preincubated with S protein-HRP (1:20,
concentration). After further washing, S protein-HRP was added to the wells that had only received
NCRD (1:5 000, concentration). Binding was detected using peroxidase substrate (TMB, Sigma,
France).
3.12. Electron Microscopy
Inactivated VACV-WR was incubated with RhSP-D for 1 h at 37°C (vol/vol). Inactivated VACVWR and RhSP-D were used as a control. After incubation 3 µl of each sample was adsorbed to a
carbon-mica interface. The carbon film with adsorbed protein was floated onto a solution of a 2%
uranyl acetate solution diluted in water. The film was then picked up by a 200 mesh copper EM grid
and finally air-dried. The samples were then transferred in an FEI Tecnai electron microscope
equipped with a CCD cold stage 2x2K camera and observed at 200 Kv.
3.13. Surface plasmon resonance analyses on immobilized SP-D
Analyses were performed using a Biacore X instrument (GE Healthcare). Recombinant human SPD and fatty acid-free BSA were diluted to 23 µg/ml in 10 mM Na acetate, pH 5.0 and 50 µg/ml in 10
mM Na acetate, pH 4.0, respectively, and immobilized on the surface of a CM5 sensor chip (GE
Healthcare) using the amine coupling chemistry until coupling levels of 10,000 RU (SP-D) and 8,800
RU (BSA) were reached. The running buffer for immobilization was 10 mM Hepes, 150 mM NaCl,
3.4 mM EDTA, pH 7.4 containing 0.005% surfactant P20 (GE Healthcare). Fifty µl of inactivated WR
virus were injected over both SP-D and the blank surface at a flow rate of 5 µl/min in 20 mM Hepes,
150 mM NaCl, 1 mM CaCl2, pH 7.4, containing 0.005% surfactant P20. Surfaces were regenerated
with 10 µl of 10 mM EDTA, pH 7.4, with an additional injection of 1 M NaCl, 10 mM EDTA, pH 7.4,
when needed. The binding curves shown are obtained after automatic subtraction of the signal
recorded on the reference surface. Injections (40 µl) of various concentrations of a mix of IAV
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hemagglutinin (Vaxigrip®) for kinetic analysis were performed under the same conditions, except that
the flow rate was set at 20 µl/min. Experiments were performed twice.
3.14. Surface plasmon resonance analyses on immobilized A27 viral protein
Recombinant viral A27 and fatty acid-free BSA were diluted to 26 and 20 µg/ml, respectively, in 10
mM Na acetate, pH 3.5, respectively and immobilized on the surface of a CM5 sensor chip using the
amine coupling chemistry until coupling levels of 600 RU (A27) and 1400 RU (BSA) were reached.
Forty µl of various lectins (SP-D, SP-A, MBL, ficolins) were injected over both A27 and the blank
surface at a flow rate of 20 µl/min in 20 mM Hepes, 150 mM NaCl, 1 mM CaCl2, pH 7.4, containing
0.005% surfactant P20 (GE Healthcare). Surfaces were regenerated with 10 µl of 1 M NaCl, 10 mM
EDTA, pH 7.4, with an additional injection of 0.1% SDS, when needed. The binding curves shown
were obtained after automatic subtraction of the signal recorded on the reference surface. Experiments
were performed twice.
3.15. Surface Plasmon resonance data evaluation
Kinetic data were analyzed by global fitting to a 1:1 Langmuir binding model of both the
association and dissociation phases for at least five concentrations simultaneously (1.7-13.7 nM SP-D,
0.5-8 nM hemagglutinin of IAV), using the BIAevaluation 3.2 software (GE Healthcare). The apparent
equilibrium dissociation constants (KD) were calculated from the ratio of the dissociation and
association rate constants (kd/ka).
3.16. Ethics Statement
Animals were housed according with the French Ethical Committee (Decree 87-848) and European
Community Directive 86/609/EEC. Experiments were carried out under the supervision of the “Comité
Consultatif pour l’Éthique en Expérimentation Animale”. The protocols were approved by the
Committee on the Ethics of Animal Experiments of the IRBA-CRSSA (Permit Number 2007/33.01).
All efforts were made to minimize suffering.
3.17. Animals
National Institutes of Health (NIH) Swiss Black SP-D+/+ and knocked out SP-D-/- mice (females and
males) were provided from Cincinnati Children’s Hospital Medical Center (Ohio, USA) [71] and
finally bred in Institute Jean Roget animal facility (La Tronche, France). Mice (four weeks old) were
quarantined for one week. General anesthesia was performed by intraperitoneal injection with a mix of
ketamine (100 mg/kg) and atropine (1.5 mg/kg). Animals were sacrificed when necessary by
intraperitoneal injection of pentobarbital (330 mg/kg). Experiment was performed three times, SP-D-/and SP-D+/+ infected-mice groups were composed of 13-16; 26-30; 32-26 animals, respectively.
Control groups, SP-D-/- and SP-D+/+ non-infected mice, were composed of 5 animals. Mice were
housed in filtered boxes and maintained under specific pathogen-free conditions. Experiments were
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performed in accordance with national guidelines governing use of laboratory animals and were
approved by the local animal care and use committee (Permit number 2007/33.1).
3.18. VACV-WR intranasal infection model
The infectious dose that was lethal to 50% of mice (LD 50) was determined by infecting black Swiss
SP-D+/+ mice (from NIH) with VACV-WR. Mice (five weeks old, 6 mice per group) were infected
intranasally with 25 µL of the VACV-WR solution containing multiple dilutions of VACV-WR (1 x
105, 5 x 105 and 1 x 106 PFU/mice). The LD50 of VACV-WR was calculated as 5 x 105 PFU. Purified
virus was diluted in F12K medium (Gibco). Mice (five weeks old) were infected intranasally with 25
µL containing 1 LD50 and control groups were instilled with 25 µL of F12K medium. Groups of mice
were monitored for mortality daily until 17 days post-infection (p.i).
3.19. Statistical analysis
For in vitro studies, the two-tailed unpaired Student’s t-test was performed. The animal survival
study was analyzed with the Log-Rank test. Values of p<0.05 were considered significant.
4. Conclusions
We demonstrate in this study that SP-D plays an important role in pulmonary host defense against
the variola virus. Using in vitro interactions, we show that SP-D blocked entry of VACV and could
provide protection against infection in vivo. Binding to SP-D was mediated by viral protein A27;
however the exact mechanism was not entirely elucidated and additional experiments would be
undertaken to precisely determine the involvement of NCRD in the interaction. In vivo experiments
also supported that SP-D was required for VACV infection. Further studies are needed to address the
potential antiviral activity of SP-D and its capacity to modulate inflammatory responses.
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